Servier will acquire Day One Biopharmaceuticals for roughly $2.5 billion. But an analyst says other companies could make ...

New findings from Spherix Global Insights’ Patient Chart Dynamix™: Lupus Nephritis (US), 2025 report reveal a treatment landscape in transition as specialists increasingly incorporate biologics, ...

Discusses Phase II Results for HLP004 in Generalized Anxiety Disorder March 5, 2026 7:30 AM ESTCompany ParticipantsMichael Cola - ...

It's no secret that many young people, particularly high school students, have a penchant for rebellion. While drugs and alcohol remain primary concerns, more and more teenagers seem to have a new ...

Hopefully this can be the first step in long overdue change that needs to occur in Britney’s life,” a representative for the ...

As “Tipper X,” a wired informant in the insider trading investigation the FBI called, Hardin had specifically been ...

Salspera is thinly capitalized, lacks institutional or strategic pharma backing, and has minimal R&D spending. Find out why ...

A federal lawsuit is challenging a Department of Veterans Affairs rule that requires disability ratings to reflect how well veterans function on medication rather than the severity of their underlying ...

Cytokinetics transitions to commercial stage with MYQORZO launch, driving 2025 revenue to $88M. Despite a widened net loss, the company advances its pipeline and eyes European expansion in 2026.

Novo Nordisk is suing a Shrewsbury doctor who sells a cheaper compounded medicine version of its popular Ozempic and Wegovy ...

Thanks to its “best-in-class” status, the bank believes the company will be the winner from a growing GLP-1 patient base.